Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of SY-009 in Healthy Subjects
NCT04119947Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of yagratide in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Number of subjects with adverse events as assessed by CTCAE V5.0 at 7 Days. Started Mar 2019; status: completed.
02
Drugs
yagratide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04119947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04119947.